Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Erschienen in: Allergo Journal 4/2019

15.06.2019 | Asthma bronchiale | Übersicht

Entwicklung der subkutanen Allergen-Immuntherapie (Teil 2): präventive Aspekte der SCIT und Innovationen

verfasst von: Ludger Klimek, Randolf Brehler, Eckard Hamelmann, Matthias Kopp, Johannes Ring, Regina Treudler, Thilo Jakob, Margitta Worm, Prof. Dr. Oliver Pfaar

Erschienen in: Allergo Journal | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die allergenspezifische Immuntherapie (AIT) durch subkutane Injektionen (SCIT) des relevanten Allergens ist die klassische kausale Behandlungsmethode IgE-vermittelter allergischer Atemwegserkrankungen und wird bereits seit über 100 Jahren erfolgreich eingesetzt.

Methoden

Für die vorliegende Publikation wurde eine selektive Literaturrecherche in Pubmed und Medline durchgeführt. Zusätzlich wurden aktuelle Publikationen deutschsprachiger Zeitschriften analysiert, die nicht in Literaturdatenbanken verfügbar sind. Diese Literaturrecherche erfasste Original- und Reviewarbeiten in deutscher oder englischer Sprache.

Ergebnisse

Für die SCIT wurden primäre, sekundäre und tertiäre Präventionseigenschaften nachgewiesen, die aber noch weiter evaluiert werden müssen. In Kombination mit Biologika kann die Sicherheit der SCIT gesteigert werden, teilweise auch die Wirksamkeit.
Adjuvanzien scheinen ein enormes Entwicklungspotenzial für die SCIT zu bergen. Bereits heute werden Aluminiumsalze, Mikrokristallines Tyrosin (MCT) und Monophosphoryl Lipid A (MPL) in kommerziellen SCIT-Präparaten eingesetzt. Parallel wird an weiteren Adjuvanzien geforscht, beispielsweise Liposomen, Mikrosphären, CpG-Motiven oder „virus-like particles“ (VLPs). Auch die Therapieextrakte selbst werden weiterentwickelt, unter anderem als rekombinante Allergene, hypoallergene Varianten wie „site-directed mutants“ (SDM), Konformationsvarianten, Allergenfragmentierungen, Allergenoligomeren, Deletionsmutanten oder Hybridallergene/Mosaikantigene.

Schlussfolgerung

SCIT-Präparationen gehören zu den innovativsten Therapiemöglichkeiten in der Immuntherapie allergischer Erkrankungen. Aufgrund zahlreicher immunologischer Ansätze werden sie die Therapie in Zukunft effektiver und sicherer machen, und das bei reduziertem Aufwand.
Literatur
1.
Distler A, Pappelendam D. 13-year overview of serious adverse drug reactions following subcutaneous specific immunotherapy with a chemically modified allergen preparation. Allergo J Int 2015;24:294–302PubMedPubMedCentralCrossRef
2.
Klimek L, Fox GC, Thum-Oltmer S. SCIT with a high-dose house dust mite allergoid is well tolerated. Safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. Allergo J Int 2018;27:131–9PubMedPubMedCentralCrossRef
3.
Brehler R, Klimek L, Vogelberg C, Werfel T, Pfaar O, Hamelmann E. Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany. Allergo J Int 2016;25:38–43PubMedPubMedCentralCrossRef
4.
Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282–319PubMedPubMedCentralCrossRef
5.
Klimek L, Chaker AM, Mösges R. [Costs of allergic diseases and saving potential by allergenspecific immunotherapy: A personal assessment]. HNO 2017;65:801–10PubMedCrossRef
6.
Reinhold T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. Allergo J Int 2017;26:7–15PubMedCrossRef
7.
Rabe U, Altengarten J, Benke E, Erdmann A, Erdmann AP, Fiedler G et al. Long-term efficacy of specific subcutaneous, short-term MPL adjuvant immunotherapy over three treatment and three follow-up years, as measured by quality of life. Allergo J Int 2017;26:147–54CrossRef
8.
9.
Nandy A, Häfner D, Klysner S. Recombinant allergens in specific immunotherapy. Allergo J Int 2015;24:143–51CrossRef
10.
Tonti E, Larché M. Concepts and perspectives on peptide-based immunotherapy in allergy. Allergo J Int 2016;25:144–153CrossRef
11.
Szépfalusi Z, Bannert C, Ronceray L, Mayer E, Hassler M, Wissmann E et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects. Pediatr Allergy Immunol 2014;25:788–95PubMedCrossRefPubMedCentral
12.
Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450–3PubMedCrossRef
13.
Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306–12PubMedCrossRef
14.
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251–6PubMedCrossRef
15.
Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year followup study. Clin Exp Allergy 2001;31:1392–7PubMedCrossRef
16.
Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295–302PubMedCrossRef
17.
Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943–8PubMedCrossRef
18.
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018;141:529–38.e13PubMedCrossRef
19.
Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010;126:942–9PubMedCrossRef
20.
Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA 2016;315: 1715–25PubMedCrossRef
21.
22.
Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274–80PubMedCrossRef
23.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al.; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134–40PubMedCrossRef
24.
Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al.; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271–9PubMedCrossRef
25.
Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125:383–9PubMedCrossRef
26.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 2011;127:1622–4PubMedPubMedCentralCrossRef
27.
Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127:1309–10.e1PubMedCrossRef
28.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013;132:1368–74PubMedPubMedCentralCrossRef
29.
Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol 2016;137:1103–10.e11PubMedCrossRef
30.
Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy 2016;14:14PubMedPubMedCentralCrossRef
31.
Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy 2018;48:232–40PubMedCrossRef
32.
33.
Stretz E, Oppel EM, Räwer HC, Chatelain R, Mastnik S, Przybilla B et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy 2017;47:1631–9PubMedCrossRef
34.
Wieczorek D, Kapp A, Wedi B. [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab]. Hautarzt 2014;65:791–5PubMedCrossRef
35.
36.
Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014;133:937–7 e2PubMedCrossRef
37.
van der Heijden FL, van Neerven RJ, Kapsenberg ML. Relationship between facilitated allergen presentation and the presence of allergen-specific IgE in serum of atopic patients. Clin Exp Immunol 1995;99:289–93PubMedPubMedCentralCrossRef
38.
Klimek L, Schmidt-Weber CB, Kramer MF, Skinner MA, Heath MD. Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol 2017;13:599–610PubMedCrossRef
39.
Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062–6PubMedCrossRef
40.
Kramer MF, Heath MD. Aluminium in allergen-specific subcutaneous immunotherapy — a German perspective. Vaccine 2014;32:4140–8PubMedCrossRef
41.
Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012;12:648–57PubMedCrossRef
42.
Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 2007;25:4575–85PubMedCrossRef
43.
Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001;69:1151–9PubMedPubMedCentralCrossRef
44.
De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008;38:2068–71PubMedCrossRef
45.
Casale TB, Stokes JR. Immunotherapy: what lies beyond. J Allergy Clin Immunol 2014;133:612–9: quiz 620PubMedCrossRef
46.
Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. J Allergy Clin Immunol 2016;137:452–61.e9PubMedCrossRef
47.
48.
49.
50.
51.
52.
Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain MT et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001;31:988–96PubMedCrossRef
53.
Bell AJ, Heath MD, Hewings SJ, Skinner MA. The adsorption of allergoids and 3-O-desacyl-4’monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy. J Inorg Biochem 2015;152:147–53PubMedCrossRef
54.
Wheeler AW, Moran DM, Robins BE, Driscoll A. l-Tyrosine as an immunological adjuvant. Int Arch Allergy Appl Immunol 1982;69:113–9PubMedCrossRef
55.
Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J Appl Toxicol 2002;22:333–44PubMedCrossRef
56.
DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239–47PubMedCrossRef
57.
Wheeler AW, Woroniecki SR. Immunological adjuvants in allergy vaccines: Past, present and future. Allergol Int 2001;50:295–301CrossRef
58.
59.
Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495–524PubMedCrossRef
60.
Klimek L, Pfaar O, Bousquet J, Senti G, Kündig T. Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Rev Clin Immunol 2017;13:897–906PubMedCrossRef
61.
62.
Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498–505PubMedCrossRef
63.
Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198–208PubMedCrossRef
64.
Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001;126:135–9PubMedCrossRef
65.
66.
Alam S, Lukawska J, Corrigan C. Adjuvants in Allergy: State of the Art. Curr Treat Options Allergy 2014;1:39–47CrossRef
67.
68.
Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010;33:848–58PubMedCrossRef
69.
Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136–43PubMedCrossRef
70.
Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al.; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–55PubMedCrossRef
71.
Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723–39PubMedCrossRef
72.
73.
Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10:787–96PubMedCrossRef
74.
Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008;389:521–36PubMedCrossRef
75.
Klimek L, Schendzielorz P, Mueller P, Saudan P, Willers J. Immunotherapy of allergic rhinitis: new therapeutic opportunities with virus-like particles filled with CpG motifs. Am J Rhinol Allergy 2013;27:206–12PubMedCrossRef
76.
Marshall JD, Abtahi S, Eiden JJ, Tuck S, Milley R, Haycock F et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001;108:191–7PubMedCrossRef
77.
Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124–34PubMedCrossRef
78.
Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470–6PubMedCrossRef
79.
Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562–70PubMedCrossRef
80.
Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41:1305–12PubMedCrossRef
81.
Klimek L, Willers J, Schendzielorz P, Kündig TM, Senti G. [Immunotherapy of allergic rhinitis without allergens?: new options for immunomodulation by vaccination with virus-like particles and CpG motifs]. HNO 2013;61:826–33PubMedCrossRef
82.
Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is The Allergen Really Needed in Allergy Immunotherapy? Curr Treat Options Allergy 2015;2:72–82PubMedCrossRef
83.
Hessel EM, Chu M, Lizcano JO, Chang B, Herman N, Kell SA et al. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005;202:1563–73PubMedPubMedCentralCrossRef
84.
Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol 2009;183:7461–70PubMedCrossRef
85.
Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004;173:531–41PubMedCrossRef
86.
87.
Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005;175:5601–5PubMedCrossRef
88.
Pang X, Chu CC. Synthesis, characterization and biodegradation of functionalized amino acid-based poly(ester amide)s. Biomaterials 2010;31:3745–54PubMedCrossRef
89.
Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M et al.; FASIT group. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018;73 Suppl 104:5–23PubMedCrossRef
90.
Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608–13PubMedCrossRef
91.
Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951–60PubMedCrossRef
92.
Kettner J, Meyer H, Cromwell O, Narkus A, Jost K. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV results of 2 years of treatment (Phase II trial). Allergy 2007;62:262
93.
Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89–97, 97.e1–14PubMedCrossRef
94.
Cromwell O, Fiebig H, Suck R, Kahlert H, Nandy A, Kettner J et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin North Am 2006;26:261–81, viiPubMedCrossRef
95.
Cromwell O, Häfner D, Nandy A. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011;127: 865–72PubMedCrossRef
96.
Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011;66:775–83PubMedCrossRef
97.
Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007;119:826–30PubMedCrossRef
98.
Cromwell O, Suck R, Kahlert H, Nandy A, Weber B, Fiebig H. Transition of recombinant allergens from bench to clinical application. Methods 2004;32:300–12PubMedCrossRef
99.
Ferreira F, Wallner M, Breiteneder H, Hartl A, Thalhamer J, Ebner C. Genetic engineering of allergens: future therapeutic products. Int Arch Allergy Immunol 2002;128:171–8PubMedCrossRef
100.
Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy 2015;5:28PubMedPubMedCentralCrossRef
101.
Klimek L, Schendzielorz P, Pinol R, Pfaar O. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Clin Exp Allergy 2012;42:936–45PubMedCrossRef
102.
Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004;134:324–31PubMedCrossRef
103.
Schendzielorz P, Klimek L. [Specific immunotherapy: clinical experience with recombinant molecular major allergens and hypoallergenic variants]. HNO 2013;61:834–42PubMedCrossRef
104.
Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761–71PubMedCrossRef
105.
106.
Pellaton C, Perrin Y, Boudousquié C, Barbier N, Wassenberg J, Corradin G et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013;3:17PubMedPubMedCentralCrossRef
107.
Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol 2016;138:162–8PubMedCrossRef
108.
Focke-Tejkl M, Weber M, Niespodziana K, Neubauer A, Huber H, Henning R et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 2015;135:1207–7.e1–11PubMedPubMedCentralCrossRef
109.
Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 2016;11:43–57PubMedPubMedCentralCrossRef
110.
Niederberger V, Neubauer A, Gevaert P, Zidarn M, Worm M, Aberer W et al. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol 2018;142:497–509.e9PubMedPubMedCentralCrossRef
111.
Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103–9.e1–7PubMedCrossRef
112.
113.
Mösges R, Kasche EM, Raskopf E, Singh J, Sohlich L, Astvatsatourov A et al. A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy 2018;73:896–904PubMedCrossRef
114.
Mösges R, Bachert C, Panzner P, Calderon MA, Haazen L, Pirotton S et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without Asthma: A randomized, multicenter, double-blind, placebo-controlled trial. Allergy 2018;73:1842–50PubMedCrossRef
115.
Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621–31PubMedCrossRef
116.
117.
Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288–96.e3PubMedCrossRef
118.
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018;73:765–98PubMedCrossRef
119.
Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2018;73:744–64PubMedCrossRef
Metadaten
Titel
Entwicklung der subkutanen Allergen-Immuntherapie (Teil 2): präventive Aspekte der SCIT und Innovationen
verfasst von
Ludger Klimek
Randolf Brehler
Eckard Hamelmann
Matthias Kopp
Johannes Ring
Regina Treudler
Thilo Jakob
Margitta Worm
Prof. Dr. Oliver Pfaar
Publikationsdatum
15.06.2019
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 4/2019
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-019-1847-4

Weitere Artikel der Ausgabe 4/2019

Allergo Journal 4/2019 Zur Ausgabe

Allergologie aktuell

Polyposis nasi: chronische Rhinosinusitis mit Nasenpolypen

AeDA/DGAKI informieren

Gemeinsam für die Zukunft der Allergologie

AeDA/DGAKI informieren

Allergietagebuch fürs Smartphone

Editorial

Schlüsselbranche Gesundheitswesen — fördern statt sparen!

Pharmaforum

Sublinguale Immuntherapie: reproduzierbare Einnahmedosis dank Dosierpumpe

Literatur kompakt

Dupilumab bei CRSwNP: Entzündungsreaktion im Gewebe deutlich reduziert

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern
weitere anzeigen

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise